drugset
drugset / Trial / NCT00688116

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

NCT00688116 ↗

Phase 1 Unknown 45 enrolled Synta Pharmaceuticals Corp.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)

Timeline

Start
2007-10
Primary completion
2014-04
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganetespib Small molecule 2 mg/m2 Other
Subject Ganetespib Small molecule 4 mg/m2 Other
Subject Ganetespib Small molecule 7 mg/m2 Other
Subject Ganetespib Small molecule 10 mg/m2 Other
Subject Ganetespib Small molecule 14 mg/m2 Other
Subject Ganetespib Small molecule 19 mg/m2 Other
Subject Ganetespib Small molecule 25 mg/m2 Other
Subject Ganetespib Small molecule 33 mg/m2 Other
Subject Ganetespib Small molecule 40 mg/m2 Other
Subject Ganetespib Small molecule 48 mg/m2 Other

Indications

cancer